The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Hiligsmann, Mickaël; Boonen, Annelies; Rabenda, Véronique; REGINSTER, Jean-Yves

doi:10.1586/erp.12.8

Download

Article (Scientific journals)

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Hiligsmann, Mickaël; Boonen, Annelies; Rabenda, Véronique et al.

2012 • In Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), p. 159-66

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/115972

DOI
10.1586/erp.12.8

PubMed
22458617

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

The importance of integrating medication adherence into pharmacoeconomic analysis.pdf

Publisher postprint (654.51 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost-effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost-effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges.

Disciplines :

Rheumatology
Special economic topics (health, labor, transportation...)

Author, co-author :

Hiligsmann, Mickaël ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique

Boonen, Annelies; Maastricht University > Internal Medicine

Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Language :

English

Title :

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Publication date :

2012

Journal title :

Expert Review of Pharmacoeconomics and Outcomes Research

ISSN :

1473-7167

eISSN :

1744-8379

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

159-66

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 April 2012

Statistics

Number of views

211 (8 by ULiège)

Number of downloads

560 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Hughes D, Cowell W, Koncz T et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10, 498-509 (2007). (Pubitemid 350013268)
Weycker D, Macarios D, Edelsberg J et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17, 1645-1652 (2006). (Pubitemid 44477625)
Kothawala P, Badamgarav E, Ryu S et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc. 82, 1493-1501 (2007). (Pubitemid 350211697)
Hiligsmann M, Rabenda V, Bruyere O et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96, 170-177 (2010).
Hiligsmann M, Rabenda V, Gathon HJ et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif. Tissue Int. 86, 202-210 (2010).
Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J. Bone Min. Res. 24, 1819-1826 (2009).
Landfeldt E, Lundkvist J, Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48, 380-388 (2011).
Hiligsmann M, Gathon HJ, Bruyere O et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13, 394-401 (2010).
Lekkerkerker F, Kanis JA, Alsayed N et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int. 18, 1311-1317 (2007). (Pubitemid 47389473)
Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 11, 44-47 (2008). (Pubitemid 351160875)
Siris ES, Selby PL, Saag KG et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med. 122, S3-S13 (2009).
Cotte FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin. Ther. 30, 2410-2422 (2008).
Kanis JA, Cooper C, Hiligsmann M et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos. Int. 22, 2563-2573 (2011).
Gold DT. Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J. Manag. Care Pharm. 12, S20-S25 (2006). (Pubitemid 47400584)
Vermeire E, Hearnshaw H, Van Royen P et al. Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26, 331-342 (2001). (Pubitemid 32989555)
Rabenda V, Reginster JY. Overcoming problems with adherence to osteoporosis medication. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 677-689 (2010).
Ross S, Samuels E, Gairy K et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14, 571-581 (2011).
Imaz I, Zegarra P, Gonzalez-Enriquez J et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos. Int. 21, 1943-1951 (2010).
Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81, 1013-1022 (2006). (Pubitemid 44175011)
Briesacher BA, Andrade SE, Yood RA et al. Consequences of poor compliance with bisphosphonates. Bone 41, 882-887 (2007). (Pubitemid 47593009)
Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 19, 811-818 (2008).
Landfeldt E, Strom O, Robbins S et al. Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish adherence register analysis (SARA). Osteoporos. Int. 23, 433-443 (2012).
Gallagher AM, Rietbrock S, Olson M et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J. Bone Miner. Res. 23, 1569-1575 (2008).
Curtis JR, Larson JC, Delzell E et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med. Care 49, 427-435 (2011).
Cadarette SM, Solomon DH, Katz JN et al. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos. Int. 22, 943-954 (2011).
Patrick AR, Schousboe JT, Losina E et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J. Clin. Endocrinol. Metab. 96, 2762-2770 (2011).
Hiligsmann M, Ethgen O, Bruyere O et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12, 687-696 (2009).
Cotte FE, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv. Res. 11, 151 (2011).
Kanis JA, Adams J, Borgstrom F et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42, 4-15 (2008).
Ström O, Borgström F, Kanis JA et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos. Int. 20, 23-34 (2009).
Jonsson B, Strom O, Eisman JA et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos. Int. 22, 967-982 (2011).
Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29, 895-911 (2011).
Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate forosteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199 (2004). (Pubitemid 38339363)
Bagger YZ, Tanko LB, Alexandersen P et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33, 301-307 (2003). (Pubitemid 37103246)
Lo JC, Pressman AR, Omar MA et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int. 17, 922-928 (2006). (Pubitemid 43781507)
Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am. J. Med. 120, 251-256 (2007). (Pubitemid 46341156)
Schousboe JT, Taylor BC, Fink HA et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298, 629-637 (2007). (Pubitemid 47236414)
Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 26, 513-536 (2008). (Pubitemid 351704859)
Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-928 (2006). (Pubitemid 44498580)
Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 21, 837-846 (2010).
Cotte FE, Cortet B, Lafuma A et al. A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75, 201-208 (2008). (Pubitemid 351418261)
Cotte FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med. Decis. Making 29, 125-139 (2009).
Earnshaw SR, Graham CN, Ettinger B et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr. Med. Res. Opin. 23, 2517-2529 (2007). (Pubitemid 350033454)
Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102, 35-42 (2009).
Hiligsmann M, McGowan B, Bennett K et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) (In press).
Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336, 1114-1117 (2008). (Pubitemid 351731741)
Breuil V, Cortet B, Cotte FE et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos. Int. 23, 445-455 (2012).
Papaioannou A, Kennedy CC, Dolovich L et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24, 37-55 (2007). (Pubitemid 46148080)
Hughes DA, Bagust A, Haycox A et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 10, 601-615 (2001). (Pubitemid 32998372)
Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59, 65-94 (2002). (Pubitemid 34098770)
Rosen AB, Spaulding AB, Greenberg D et al. Patient adherence: a blind spot in cost-effectiveness analyses? Am. J. Manag. Care 15, 626-632 (2009).
Cherry SB, Benner JS, Hussein MA et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 12, 489-497 (2009).
Breitscheidel L, Stamenitis S, Dippel FW et al. Economic impact of compliance to treatment with antidiabetes medication in Type 2 diabetes mellitus: a review paper. J. Med. Econ. 13, 8-15 (2010).
Salas M, Hughes D, Zuluaga A et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 12, 915-922 (2009).
Cleemput I, Kesteloot K, Vanrenterghem Y et al. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 22, 1217-1234 (2004). (Pubitemid 40075723)